FDA Approves Tisotumab Vedotin-Tftv for Recurrent or Metastatic Cervical Cancer
On April 29, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv (Tivdak®) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previouslyreceivedaccelerated approval for the indication.